Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CX11 (VCT220)
CX11 · 3 trials · 4 indications
AUC0-24 of of CX11 (VCT220)
Cmax of CX11 (VCT220)
Tmax of CX11 (VCT220)
| Arm | Type | Description |
|---|---|---|
| Placebo group | PLACEBO_COMPARATOR | - |
| 40 mg group | EXPERIMENTAL | - |
| 80 mg group | EXPERIMENTAL | - |
| 120 mg group | EXPERIMENTAL | - |
| 160 mg group | EXPERIMENTAL | - |
| 200 mg group | EXPERIMENTAL | - |
| 200 mg fast titration group | EXPERIMENTAL | - |
| 200 mg slow titration group | EXPERIMENTAL | - |
| Fasted-Fed Arm | EXPERIMENTAL | Fasted-Fed Group |
| Fed-Fasted Arm | EXPERIMENTAL | Fed-Fasted Group |
| Name | Type | Description |
|---|---|---|
| CX11 | DRUG | CX11 tablets administered orally once daily (QD) |
| Placebo | OTHER | Matching placebo tablets administered orally once daily (QD) |
| CX11 (VCT220) | DRUG | CX11 (VCT220) administered orally to participants who are in fasted/fed state in the first 6 consecutive days, and in fed/fasted state on the 7th day |
Inclusion Criteria Participants who meet all of the following criteria will be eligible to participate in this study: * Adults aged 18 to 75. * Diagnosis of type 2 diabetes for at least 6 months. * HbA1c between 7.0% and 10.5%. * Body mass index (BMI) between 23 and 50 kg/m². * Body weight stable ...
Top 20 of 32 competitors
CX11 is an investigational small molecule being developed for Type II Diabetes Mellitus, Obesity, and Obesity & Overweight. It is currently in Phase 2 clinical development for these metabolic conditions.
CX11 is being developed by Milestone Pharmaceuticals Inc., a biopharmaceutical company traded on the stock exchange under the ticker MIST.
CX11 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its efficacy and safety.
CX11 is being studied in several trials. NCT07011797 is a completed Phase 2 study in overweight/obese participants. NCT07340320 is a recruiting Phase 2 trial in Type 2 Diabetes Mellitus. NCT07349381 is a recruiting Phase 1 food-effect study in healthy participants.
Yes, CX11 is also known as CX11 (VCT220). Both names refer to the same investigational drug being developed by Milestone Pharmaceuticals Inc.
The molecular target or target class for CX11 has not been disclosed in available information. Therefore, its specific mechanism of action is not described here.